Companies: 10,795·Total market cap: $144.5T
Caris Life Sciences, Inc.

Caris Life Sciences, Inc.

CAINASDAQHealthcare● Active
$16.14
$-0.35(-2.12%)
Market Cap$4.6B
P/E Ratio—
52W High$42.5
52W Low$14.19
SEC Filings

Caris Life Sciences, Inc. (CAI) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0002019410 · CAI · NASDAQ · as of Jun 8, 2026

Filing snapshot

105
Total Filings
8-K
Latest Form
2026-06-05
Most Recent
2025
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0002019410 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-03
Fiscal Year End
Mar 3, 2026
Accession No.
0002019410-26-000016
Primary Document
cai-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0002019410 · Accession 0002019410-26-000016

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-08
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-05Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-05
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-12
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-12
View
10-QQuarterly Report
10-Q
2026-05-08
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEF 14AProxy Statement
DEF 14A
2026-04-23
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-07
View
8-KCurrent Report
8-K
2026-04-02
View
10-KAnnual Report
10-K
2026-03-03
View
8-KCurrent Report
8-K
2026-02-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-05
View
8-KCurrent Report
8-K
2026-01-12
View
Showing 1–15 of 66 filingsForm 4 / 144 hidden· 105 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0002019410  |  Exchange: NASDAQ · Healthcare

Caris Life Sciences, Inc. (NASDAQ: CAI) has submitted 105 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0002019410, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Caris Life Sciences, Inc.'s most comprehensive regulatory disclosure. The most recent Caris Life Sciences, Inc. 10-K was filed on 2026-03-03 for fiscal year ending 2026. Historical CAI 10-K annual reports are available from 2024 through 2026.

Investors researching Caris Life Sciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
MRNA SEC Filings →JAZZ SEC Filings →MDGL SEC Filings →CYTK SEC Filings →HALO SEC Filings →CORT SEC Filings →MRUS SEC Filings →ABVX SEC Filings →
→ CAI Financials→ CAI Earnings→ CAI Insider Trades

Frequently Asked Questions

CAI SEC Filings · 8 questions

Caris Life Sciences, Inc. (CAI) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 105 filings and access original documents at no cost. Caris Life Sciences, Inc.'s CIK is 0002019410.

CAI SEC filingsCaris Life Sciences, Inc. SEC documentsfind CAI 10-K